A decrease in the pro-inflammatory cytokine IL-6 was also appreciated in a study examining CdM as a therapy for renal fibrosis and in a pulmonary fibrosis meta-analysis conducted by Srour et al [37]. This evidence concerns the gene IL6 and renal fibrosis.